HALO — Halozyme Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual balance sheet for Halozyme Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	368	741	363	336	596
Net Total Accounts Receivable
Net Total Receivables	97.7	91	231	234	308
Total Inventory
Prepaid Expenses
Total Current Assets	555	926	739	746	1,085
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	10.6	8.79	75.6	74.9	75
Net Goodwill
Net Intangible Assets
Other Long Term Assets
Total Assets	580	1,104	1,842	1,733	2,063
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	421	117	131	112	139
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	429	907	1,672	1,649	1,700
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	151	197	170	83.8	364
Total Liabilities & Shareholders' Equity	580	1,104	1,842	1,733	2,063
Total Common Shares Outstanding